Keyphrases
Gastroesophageal Adenocarcinoma
70%
ER Expression
50%
Estrogen Receptor Status
50%
Therapeutic Relevance
50%
Response Signature
50%
Female Sex
50%
Clinical Treatment
50%
DNA Damage
50%
Immune Response
50%
Clinical Impact
50%
Epidermal Growth Factor Receptor
41%
Tumor Microenvironment
33%
Tumor Samples
20%
Overall Survival
18%
Immunohistochemistry
18%
Cold Tumor
16%
Immune Checkpoint Inhibitors
16%
Tumor
16%
Transcriptional Profiling
16%
Chemotherapy
16%
Clinical Trials
10%
Poor Prognosis
10%
Patient Cohort
10%
Disease Biology
10%
Survival Impact
10%
Young Age
10%
Survival Outcomes
10%
Older Adults
10%
Expression Level
10%
Frail Elderly
10%
Palliative Chemotherapy
10%
Advanced Gastroesophageal Cancer
10%
Estrogen Receptor
10%
MiRNA Signature
8%
CD274
8%
Immune Checkpoint Inhibitor Response
8%
Inflamed Tumors
8%
Radiological Response
8%
Fluorescence in Situ Hybridization
8%
DNA Damage Repair
8%
Epidermal Growth Factor Receptor Inhibitors
8%
Dose Level
8%
Programmed Death-ligand 1 (PD-L1)
8%
Microsatellite Instability-high (MSI-H)
8%
Immune Cells
8%
Platinum-based Chemotherapy
8%
Dose Effect
8%
Chemotherapy Response
8%
Path Analysis
8%
Predictive Role
8%
Medicine and Dentistry
Adenocarcinoma
100%
Neoplasm
66%
Chemotherapy
66%
Post-Hoc Analysis
50%
Disease
50%
Immune Response
50%
Receptor Expression
50%
DNA Damage
50%
Estrogen Receptor
50%
Epidermal Growth Factor Receptor
41%
Tumor Microenvironment
33%
Overall Survival
33%
Immunohistochemistry
33%
Immune Checkpoint Inhibitor
25%
Clinical Trial
25%
Malignant Neoplasm
25%
Gene Expression Profiling
16%
Immunity
16%
Immunocompetent Cell
8%
Programmed Death 1 Ligand 1
8%
Cross-Validation
8%
DNA Repair
8%
Epidermal Growth Factor Receptor Kinase Inhibitor
8%
Microsatellite Instability
8%
Biological Marker
8%
Fluorescence in Situ Hybridization
8%
Biochemistry, Genetics and Molecular Biology
DNA Damage
50%
Estrogen Receptor
50%
Immune Response
50%
Epidermal Growth Factor Receptor
50%
Overall Survival
33%
Clinical Trial
25%
Immune Checkpoints
25%
Gene Expression Profiling
16%
Immunity
16%
DNA Repair
8%
Fluorescence in Situ Hybridization
8%
Growth Factor Receptor Inhibitor
8%
Immunocompetent Cell
8%
RNA
8%
Microsatellite Instability
8%